NeuroSense Therapeutics Provides CEO’s Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

As Q3 comes to a close, we would like to share the progress we’ve made at NeuroSense with PrimeC, our novel combination drug for ALS which is now in a Phase IIb study.


Join Our Newsletter

Skip to content